JP2017525752A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525752A5
JP2017525752A5 JP2017515008A JP2017515008A JP2017525752A5 JP 2017525752 A5 JP2017525752 A5 JP 2017525752A5 JP 2017515008 A JP2017515008 A JP 2017515008A JP 2017515008 A JP2017515008 A JP 2017515008A JP 2017525752 A5 JP2017525752 A5 JP 2017525752A5
Authority
JP
Japan
Prior art keywords
amino acid
substantially pure
acid seq
protein
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032807 external-priority patent/WO2015184050A1/en
Publication of JP2017525752A publication Critical patent/JP2017525752A/ja
Publication of JP2017525752A5 publication Critical patent/JP2017525752A5/ja
Pending legal-status Critical Current

Links

JP2017515008A 2014-05-28 2015-05-28 静注用免疫グロブリンの精製組成物及びリンパ球を調整しb型肝炎を治療するためのkhタンパク質 Pending JP2017525752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
US62/003,664 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (2)

Publication Number Publication Date
JP2017525752A JP2017525752A (ja) 2017-09-07
JP2017525752A5 true JP2017525752A5 (enExample) 2018-05-17

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515008A Pending JP2017525752A (ja) 2014-05-28 2015-05-28 静注用免疫グロブリンの精製組成物及びリンパ球を調整しb型肝炎を治療するためのkhタンパク質

Country Status (10)

Country Link
EP (1) EP3148574B1 (enExample)
JP (1) JP2017525752A (enExample)
CN (1) CN107106664A (enExample)
AU (1) AU2015266997A1 (enExample)
BR (1) BR112016027818A2 (enExample)
CA (1) CA2949994A1 (enExample)
ES (1) ES2878043T3 (enExample)
MX (1) MX2016015574A (enExample)
RU (1) RU2016151761A (enExample)
WO (1) WO2015184050A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2878043T3 (es) 2014-05-28 2021-11-18 Rare Antibody Antigen Supply Inc Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
CN118903378A (zh) * 2024-03-19 2024-11-08 北京达尔文细胞生物科技有限公司 一种蛋白聚合物在治疗渐冻症中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) * 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
JP5969458B2 (ja) * 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
SG185483A1 (en) * 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
TW201335181A (zh) * 2012-01-31 2013-09-01 Kieu Hoang 55種新發現的蛋白質之序列及其應用
ES2878043T3 (es) 2014-05-28 2021-11-18 Rare Antibody Antigen Supply Inc Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B

Similar Documents

Publication Publication Date Title
CN102124027B (zh) 产生富含分泌型免疫球蛋白的乳组分的方法
JP2017525752A5 (enExample)
SA520411930B1 (ar) وسيلة وطريقة لتحضير الموجهات الفيروسية واستخداماته
WO2014160463A8 (en) Prefusion rsv f proteins and their use
RU2015151869A (ru) Способ непрерывной многостадийной очистки антител
JP2012528190A5 (enExample)
FI4104859T3 (fi) Menetelmä vasta-aineiden ja niiden terapeuttisten tuotteiden väkevöimiseksi
JP2016519137A5 (enExample)
JP2014506790A5 (enExample)
BR112018016944A2 (pt) composições funcionais derivadas de feijão mungo
MX2013006611A (es) Tratamiento de formaciones iliticas al usar un agente quelante.
JP2013528183A5 (enExample)
JP2011524887A5 (enExample)
WO2014004436A3 (en) Crystalline anti-human il-23 antibodies
RU2014125063A (ru) Очистка белка с использованием бис-трис буфера
JP2013516432A5 (enExample)
JP2009225809A5 (enExample)
CN102532307A (zh) 一种制备人免疫球蛋白的方法
RU2016151761A (ru) Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b
HRP20200710T1 (hr) Novi postupak za efikasno pročišćavanje humanog serumskog albumina
CN102199198A (zh) 人呼吸道合胞病毒f蛋白的纯化方法
CA2922996C (en) Treated filter
RU2015155602A (ru) Способ получения аполипопротеина a-i (аро a-i)
CN103642760B (zh) 一种制备柯萨奇a16型病毒完整实心颗粒的方法
HRP20200588T1 (hr) Završno filtriranje u više koraka